

Dr Malgorzata Wamil MD, MSc, PhD, MRCP, FESC

Assistant Professor and Consultant Cardiologist specialising in non-invasive cardiovascular imaging (cardiac MRI, CT and echocardiography), heart failure and inherited cardiomyopathies and clinician scientist at the University of Oxford; trained in medicine and cardiology at the Oxford University Hospitals, completed MSc in Research and British Heart Foundation PhD in Cardiovascular Science at the University of Edinburgh; further post-doctoral research fellowship in Cardiovascular Imaging at the Oxford University, a clinical post-CCT fellowship in Heart Failure/ICC and MSc in Clinical Trials sponsored by European Society of Cardiology at the University of Oxford. Research experience spans basic science and drug development projects, translational clinical studies, and randomised controlled trials.



Education/Qualifications

2022-2024	University of Oxford, MSc in Clinical Trials , funded by European Society of Cardiology grant
2021	Oxford Executive Leadership Certificate , Said Business School, University of Oxford
2018	SCMR and EACVI level 3 accreditation in CMR
2017	Dual CCT in Cardiology and General Medicine , Oxford University Hospitals
2017, 2021	SCCT Cardiac CT accreditation
2017, 2023	EACVI Cardiac MRI level 3 accreditation
2016, 2023	Transoesophageal Echo European Society of Cardiology accreditation
2013	The European Examination in General Cardiology (BCS, Knowledge-Based Assessment)
2013, 2018, 2023	Transthoracic Echo British Society of Echocardiography accreditation
2010	United States Postgraduate Medical Licensing Examination- USMLE Step 3
2009	MRCP (London)
2008	4-year BHF PhD in Cardiovascular Science , University of Edinburgh
2007	ECFMG Certificate, United States Medical Licensing Examination USMLE Step 1, Step 2, Step 2 CS
2005	MSc in Cardiovascular Research , University of Edinburgh, with distinction
2003	Doctor of Medicine & Surgery , with distinction, top of my year Medical University of Warsaw and Freie Universitaet in Berlin

Academic Awards/Prizes

2023	Assistant Professor of Medicine, Mayo Clinic, Rochester, USA
2022-24	European Association of Cardiovascular Imaging Leaders of Tomorrow programme
2022-24	European Society of Cardiology educational grant to cover the cost of the MSc in Clinical Trials programme at the University of Oxford, Green Templeton College
2015-17	British Heart Foundation Oxford University Centre of Research Excellence fellowship award
2004-18	British Heart Foundation 4-year MSc-PhD fellowship grant, University of Edinburgh
2003	Chancellor of the Medical University of Warsaw Prize for excellence
2001	Polish Ministry of Health Award, a scholarship for the best medical student in Poland
2001	International Federation of Medical Students' Association, IFMSA award, Muenster Universitaet, Germany
2001	DAAD- German Government Academic Exchange Award for the outstanding medical student
2000	Erasmus Socrates Scholarship to continue medical school at the Freie Universitaet in Berlin

Funding History

As Principal Investigator

2017	Oxfordshire Health Services Research Fund (OHSRC), research grant, 'The mechanism of adverse cardiac remodelling in diabetic patients after myocardial infarction- OxAMI-Diabetes sub-study', £8,200
2016	BHF, Oxford University CRE 16 months postdoctoral part-time fellowship covering 40% salary, £36,000
2016	Oxford University, Returning Career Fund Award, secondment in Prof M Nahrendorf's lab in MGH, Harvard University, £4,250
2004	British Heart Foundation 4-year MSc-PhD fellowship (salary and research grant), £220,000

As Co-Applicant

2007	Supervisor to J Street, BHF funded MSc student, 'The role of 11bHSD1 in the metabolism of oxysterols'
------	---

Employment History

12/2020-	Part-time consultant cardiologist, Mayo Clinic Healthcare in London (cardiac imaging, 40%-time commitment)
04/2019-	Consultant cardiologist specialising in cardiac imaging, heart failure and cardiomyopathies, Great Western Hospital in Swindon (60%-time commitment)

05/2018-01/2019	Post CCT fellow in Heart Failure and Inherited Cardiomyopathies, Oxford Deanery, JRH, Oxford
06/2018-07/2018	Locum Consultant in Acute Medicine, John Radcliffe Hospital, Oxford
11/2017-04/2018	Locum consultant cardiologist specialising in cardiovascular imaging (non-invasive management of coronary artery disease- stress echo, perfusion CMR, CTCA), maternity cover, Royal Berkshire Hospital, Reading
01/2015-11/2017	Postdoctoral research fellow, Acute Vascular Imaging Centre, Oxford University
09/2017-11/2017	ST8 General Medicine, John Radcliffe Hospital
08/2013-08/2017	ST6-ST7 Cardiology NTN with sub-speciality in cardiovascular imaging, John Radcliffe Hospital
10/2010-08/2013	ST3-ST5 Cardiology with NTN, Oxford Deanery
08/2010-10/2010	LAT General Medicine Speciality Registrar, John Radcliffe Hospital
08/2008-07/2010	Core Medical Training CT1-CT2, Oxford University Hospitals
02/2008-08/2008	Senior House Officer, Royal Infirmary, Little France, Edinburgh
09/2004-08/2008	BHF MSc-PhD fellow, University of Edinburgh
07/2003-10/2004	House officer in Medicine and Surgery
03/2002-10/2002	Research Assistant, Haematology Laboratory, Humboldt University, Berlin

Leadership role

2022-24	Vice-Chair of Mayo Clinic International Research and Education Committee
2021-22	Mayo Clinic Healthcare in London, Steering Committee member, lead of service expansion program
2020-	NICE Diabetes Pharma advisor
2020-	Clinical Lead of Cardiac Imaging service at the Mayo Clinic Healthcare in London
2019-	Clinical Lead of Cardiac MRI service at the Great Western Hospital NHS Trust
2019-	Clinical Lead of Inherited Cardiac Conditions Clinic at the Great Western Hospital NHS Trust

Research positions

2023-	Assistant Professor of Medicine, Mayo Clinic, Rochester, USA
2020-	Honorary Post-doctoral Research Fellow, Deep Medicine, University of Oxford
2018-2020	Honorary Post-doctoral Research Fellow, Diabetes Trial Unit, University of Oxford
2016-2018	British Heart Foundation Centre of Excellence post-doctoral fellowship in Cardiovascular Imaging, University of Oxford
2004-2008	4-year British Heart Foundation MSc-PhD programme in Cardiovascular Science and Diabetology
1999-2003	Research Assistant, Polish Academy of Science and Haematology Department at the Humboldt University

Academic training

2022	EACVI Leaders of Tomorrow 2-year mentored programme
2022	MSc in Clinical Trials, 2-year studies at the University of Oxford
2021	Oxford Executive Leadership Programme, Said Business School, Oxford University
2019	London CT TAVI course
2017	Level 3 Cardiac CT course, Plymouth
2017	IRMER course
2010,17, 22	ALS course
2017	SCMR workshop, 'CMR for probing mechanisms of heart disease: micro to macro to model', Washington
2017	Academic Writing course, Oxford University
2016	Level 2 Cardiac CT course, Harefield CT course
2016	Medical Statistics course, Oxford University
2015	SCMR, CMR physics course, Nice
2014	Perioperative TOE course, Heart Hospital
2011-2016	Cardiac Imaging Programme of the Royal Society of Medicine
2010-2011	Multimodality Cardiovascular Imaging Symposium, Oxford University
2010	Handheld echocardiography course, Ealing Hospital
2010, 2015	Good Clinical Practice, Oxford University
2008	British Heart Foundation Fellow Days, Cambridge University
2007	Statistics for Clinical Researchers, Wellcome Trust and University of Edinburgh, 3-month course
2006	Microarray and bioinformatics course, BHF and University of Edinburgh
2004	Animal Handling and Animal Surgery course, University of Edinburgh
2004	Radiation course, University of Edinburgh
2001	Drug development, 3-month course, Schering, Humboldt University, Berlin

Teaching

2023-	Teaching Associate , Green Templeton College, University of Oxford
2019-2022	Bristol Medical School Tutor , regular seminars for Years 3 and 4; 'The pathophysiology and pharmacology of the coronary artery disease.'

2018, 2020	Oxford Deanery Teaching Programme for Cardiology Registrars organiser ; presented a lecture on 'The modern role of TOE in management of valvular pathologies and structural heart disease.'
2015-2017	Bucks FICE course organiser , run echo course for intensive care specialists (approved by BSE)
2009-2017	PACES bedside teaching to medical doctors, Oxford University Hospitals
2009-2014	Green Templeton College Oxford University Tutor , regular weekly bedside teaching for Y4 students; 2-3 lectures per year for Y4 medical students; cardiac physiology for Y1 graduate entry medical students.
2012-2013	Wycombe General Hospital Foundation Years Programme Tutor ; regular weekly lectures and seminars in General Medicine and Cardiology for junior doctors
2007	Supervisor of BHF MSc student during his final research project
2001-2002	Immunology Tutor , University of Warsaw, regular weekly seminars for undergraduate students

Membership of Professional Organisations

2020-present	European Association of Cardiovascular Imaging, Leaders of Tomorrow programme
2019-present	NICE Diabetes Pharma committee member/cardiology advisor
2016-present	Society of Cardiovascular Computed Tomography
2014-present	Society of Cardiovascular Magnetic Resonance
2011-present	Royal Colleges of Physicians training board
2010-present	European Association of Cardiovascular Imaging member
2007-present	Royal College of Physicians of London
2010-present	British Society of Echocardiography
2005-present	European Society of Cardiology (Fellow since 2022)

Textbook/Chapter Contributions

1. Oxford Specialist Handbooks in Cardiology, 3rd edition, Chapter 5 Transoesophageal examination. Leeson P, Becher H, **Wamil M**. In Press

Editorial roles

I am the editor of a research topic for the journal **Frontiers in Cardiovascular Medicine**, which focuses on the role of multimodality imaging in diagnosing and managing cardiomyopathies (2024).

Publications

1. Rao S, Li Y, Mamouei M, Salimi-Khorshidi G, **Wamil M**, Nazarzadeh M, Yau C, Collins G, Jackson R, Vickers A, Danaei G, Rahimi K Refined selection of individuals for preventive cardiovascular disease treatment with a Transformer-based risk model **BMJ** (accepted)
 2. Challa A, Negm A, Mahayni A, **Wamil M**, Williamson E, Guerrero M, Weishaar P, Collins J. Transcatheter Mitral Valve Replacement: Treatment Planning With Computed Tomography **Seminars Roent**. 2024 Jan;59(1):67-75
 3. **Wamil M**, Nazarzadeh M, Rahimi K Blood pressure management in type 2 diabetes: a review of recent evidence, **Heart** (accepted July 2024)
 4. **Wamil M**, Goncalves M. Multi-modality cardiac imaging confirms quadricuspid aortic valve and excludes papillary fibroelastoma, **EHJ-IMP** April 2024
 5. Hewitson LJ, Cadiz S, Al-Sayed S et al, **Wamil M**, Panoulas V, Rahbi H Time to TAVI: streamlining the pathway to treatment, **Open Heart**, 2023 Sep ; 10(2):e002170
 6. **Wamil M**, Hassaine A, Rao S, Li Y, Mamouei M, Canoy D, Nazarzadeh M, Bidel Z, Copland E, Rahimi K and Salimi-Khorshidi G, Stratification of diabetes in the context of comorbidities, using representation learning and topological data analysis; **Scientific Reports**, 2023 Jul16;13(1):11478
 7. Roca-Fernández A, **Wamil M**, Telford A, Thomaidis-Brears H, Dennis A, Banerjee R, Robson M, Bull S, Ntusi N, Banerjee A, Cardiovascular impairment in Long Covid 1-year post-SARS-CoV-2 infection, **Open Heart 2023 Feb;10(1): e002241**
 8. **Wamil M**, Goncalves M, Rutherford A, Borlotti A, Pellikka PA, Multi-modality cardiac imaging in the management of diabetic heart disease **Frontiers of Cardiovascular Medicine**
 9. Nazarzadeh M, Bidel Z, Canoy D, Copland E, Bennett AD, Dehghan A, Smith GD, Holman RR, Woodward M, Gupta A, Adler AI, **Wamil M**, Sattar N, Cushman WC, McManus RJ, Teo K, Davis BR, Chalmers J, Pepine CJ, Rahimi K, Blood Pressure Lowering Treatment Trialists' Collaboration Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis, **Lancet Diabetes Endocrine** 2022 Sep;10(9):645-654.
-

-
10. Rahimi K, McManus R, **Wamil M**, Chalmers J, Canoy D Blood pressure meta-analysis highlights an implementation gap, **Lancet**, 2022 Apr 9;399(10333):1380.
11. Rahimi K, Bidel Z, Nazarzadeh M, Coplan E, Canoy D, **Wamil M**, Majert J, McManus R; Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis, **Lancet** 26 Aug 2021 S0140-6736(21)01921-8.
12. Nazarzadeh M, Bidel Z, Coplan E, Canoy D, **Wamil M**, Majert J, Byrne K, Sundstrom J, Teo K, Davis B, Chalmers J, Pepine C, Dehghan A, Bennett D, Smith D, Rahimi K; Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis., **Lancet** November 2021 13;398(10313):1803-1810. doi: 10.1016/S0140-6736(21)01920-6.
13. **Wamil M**, Coleman R, Adler IA, McMurray J, Holman RR; Increased Risk of Incident Heart Failure and All-cause Mortality in People with Insulin Resistance in the United Kingdom Prospective Diabetes Study: UKPDS; **Diabetes Care** 2021 Aug;44(8):1877-1884
14. Dennis A, **Wamil M**, Alberts J, Oben J, Cuthbertson DJ, Wootton D, Crooks M, Gabbay M, Brady M, Hishmeh L, Attree E, Heightman M, Banerjee R, Banerjee A; COVERSCAN study investigators; Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study **BMJ Open** 2021 Mar 30;11(3): e 048391
15. **Wamil M**, McMurray JJ, Scott CAB, Coleman RL, Sun Y, Standl E, Rydén L, Holman RR Incidence, predictors, and importance of heart failure events in patients with impaired glucose tolerance in the Acarbose Cardiovascular Evaluation (ACE) trial, **Diabetes Research and Clinical Practice** 2020 Dec 170:108488
16. **Wamil M**, Borlotti A, Briosa e Gala A, Bracco A, Liu D, Piechnik S, Ferreira V, Alkalil M, DeMaria G, Fahrni G, Dawkins S, Wolfrum M, Banning A, Kharbanda R, Neubauer S, Choudhury R, Channon K, Dall'Armellina E Combined T1-mapping and tissue tracking analysis improves assessment of adverse LV remodeling following acute STEMI- an Oxford Acute Myocardial Infarction (OxAMI) study **International Journal of Cardiovascular Imaging** 2019 Jul, 5(7):1297-1308
17. De Ferrari G, Stevens S, Ambrosio G, Leonardi S, McGuire DK, Armstrong PD, Green JB, **Wamil M**, Holman RR, Peterson ED; on behalf of the TECOS Study Group; Low-Density Lipoprotein Cholesterol Treatment Patterns and Associated Outcomes in Patients with Type 2 Diabetes and Established Cardiovascular Disease: Insights from TECOS, **American Heart Journal** 2020 Feb;220:82-88
18. **Wamil M**, Bull S and Newton J. The modern role of transoesophageal echocardiography in the management of valvular pathologies. **Echo Research and Practice** Jan 17
19. **Wamil M**, Newton J and Bull S. TOE-what a general cardiologist needs to know? **Heart** 2017 Apr;103(8):629-640
20. Bajgent C, Laundry M et al. Collins R and **SHARP Investigators**. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial **Lancet** 2011 Jun 9; 377(9784): 2181–2192
21. Digby, J, Martinez F, Jefferson A, **Wamil M**, Ruparella N, Greaves D and Choudhury R. Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. **Atherosclerosis, Thrombosis and Vascular Biology** 2012 Mar;32(3):669-76.
22. **Wamil M**, Battle JH, Turban S, Kipari T, Peixoto RS, Fernbach D, Ramage L, Chapman KE, Hughes J, Dunbar D, Seckl JR and Morton NM. Depot-specific insulin-sensitization and reduced inflammation drives the protective fat distribution of 11 β -HSD1 $^{-/-}$ mice. **Diabetes** 2011, Apr;60(4):1158-67.
23. **Wamil M**, Andrew R, Chapman K, Street J, Morton NM, Seckl JR. 7-oxysterols modulate glucocorticoid activity in adipocytes. **Endocrinology**. 2008, Dec;149(12):5909-18
24. **Wamil M.**, Seckl JR. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. **Drug Discovery Today**. 2007, Jul; 12(13-14):504-520.
25. Morton NM, Densmore V, **Wamil M**, Ramage L, Nichol K, Bünger L, Seckl JR and Kenyon CJ. A polygenic model of the metabolic syndrome with reduced circulating and intra-adipose glucocorticoid action **Diabetes**. 2005, Dec; 54(12):3371-8.
26. Snarski E, Kedzierska M, **Wamil M**, Prejbisz A, Pedzisz P, Wiktor-Jedrzejczak W. (2002, February 1). Time till diagnosis in blood neoplasia - an index of the efficiency of health care system? Acta Hematologica 33, 257-262.
27. Szopa M, **Wamil M**. (2007, May 20). 11beta-hydroxysteroid dehydrogenase type 1 inhibitor: a novel therapeutic target in the metabolic syndrome. Diabetologia Praktyczna 8, 77-83.
-

28. Maurin JK, Lasek W, Gorska A, Switaj T, **Wamil M**, Mlynarczuk I, Kazimierczuk Z. Synthesis, structure and tumour necrosis factor-alpha production-enhancing properties of novel adamantylamino heterocyclic derivatives. *Anticancer Drug Design* 2001, Apr; 16(2-3):73-80.

Submitted/in revision:

29. C Apurva, M Radike, **M Wamil**, N Weber, E Wiliamson Dynamic evaluation of mitral valve geometry in primary and functional mitral regurgitation using multiphase computed tomography: Implications of sex differences for transcatheter mitral valve repair. *Scientific Reports* (in revision)

30. C Apurva, M Radike, **M Wamil**, N Weber, E Wiliamson Interobserver and Intraobserver Variability Among Different Vendors for Mitral Valve Assessment: Implications for Transcatheter Mitral Valve Repair, submitted

31. **Wamil M**, K Rahimi Blood pressure management in type 2 diabetes: a review of recent evidence **Heart** (accepted) August 2024

Presentations

1. Increased Risk of Incident Heart Failure and All-cause Mortality in People with Insulin Resistance in the United Kingdom Prospective Diabetes Study: UKPDS, accepted for ADA 2020, Chicago
2. The mechanism of adverse cardiac remodeling after myocardial infarction in the diabetic heart, European Society of Cardiology, Paris 2019
3. Combined T1-mapping and tissue tracking analysis improves assessment of adverse LV remodelling following STEMI; SCMR Washington, USA 2017
4. Cardiovascular imaging in coronary artery disease; invited talk NIH, Washington, USA 2014
5. Adipose tissue transcriptome profile underlying the protective phenotype of 11beta-HSD1-/- mice. ENDO 2008, San Francisco, USA 2008
6. 7-oxysterols modulate glucocorticoid activity in adipocytes. Keystone Symposia, Nuclear Receptor Pathways to Metabolic Regulation; Steamboat Springs, USA, 2008
7. 7-oxysterols modulate glucocorticoid activity. 2nd Integrative Physiology Post-Graduate Conference, University of Aberdeen, 2008
8. The role of 11beta-HSD1 in macrophage accumulation in adipose tissue. Centre for Cardiovascular Science Symposium; Edinburgh, 2007
9. 11beta-hydroxysteroid dehydrogenase type 1: key regulator of oxysterol metabolism. Society for Endocrinology BES; Birmingham, 2007